within Pharmacolibrary.Drugs.ATC.M;

model M04AX01
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.00075,
    adminDuration  = 600,
    adminMass      = 0.0002,
    adminCount     = 1,
    Vd             = 0.00017,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Urate oxidase (rasburicase) is an enzyme that catalyzes the oxidation of uric acid to allantoin, a more soluble compound. It is used to reduce plasma uric acid levels and is primarily indicated for the management and prevention of hyperuricemia in patients undergoing chemotherapy for hematologic malignancies at high risk for tumor lysis syndrome. It is approved for clinical use in several countries.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters after intravenous administration of urate oxidase in adult patients with hematologic malignancies or solid tumors; data primarily reflect patients aged 18-75 years.</p><h4>References</h4><ol><li><p>Easton, J, et al., &amp; Jarvis, B (2001). Rasburicase. <i>Paediatric drugs</i> 3(6) 433–439. DOI:<a href=&quot;https://doi.org/10.2165/00128072-200103060-00004&quot;>10.2165/00128072-200103060-00004</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11437188/&quot;>https://pubmed.ncbi.nlm.nih.gov/11437188</a></p></li><li><p>Sun, F, et al., &amp; Cao, Y (2023). Randomized, Double-Blind, Placebo-Controlled, Phase I, Dose- Escalation Study to Evaluate the Tolerance, Pharmacokinetics, Pharmacodynamics and Immunogenicity of PEGylated Urate Oxidase for Injection in Healthy Adults and Hyperuricemia Volunteers: Study Protocol. <i>Diabetes, metabolic syndrome and obesity : targets and therapy</i> 16 4263–4268. DOI:<a href=&quot;https://doi.org/10.2147/DMSO.S429114&quot;>10.2147/DMSO.S429114</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38164417/&quot;>https://pubmed.ncbi.nlm.nih.gov/38164417</a></p></li><li><p>Sundy, JS, et al., &amp; Hershfield, MS (2007). Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. <i>Arthritis and rheumatism</i> 56(3) 1021–1028. DOI:<a href=&quot;https://doi.org/10.1002/art.22403&quot;>10.1002/art.22403</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/17328081/&quot;>https://pubmed.ncbi.nlm.nih.gov/17328081</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end M04AX01;
